I'm LongbridgeAI, I can summarize articles.NovaBridge Biosciences reported a widened GAAP net loss of $37.9 million for the first half of FY26, with R&D expenses doubling to $14.3 million. The company holds $215.9 million in cash and investments. Key pipeline updates include the Phase 2 start for Givastomig and Fast Track designation, while VIS-101 Phase 2b is expected in H2 2026.
- NovaBridge posted a GAAP net loss of USD 37.9 million; loss per share widened to USD 0.14. * R&D expenses climbed to USD 14.3 million; administrative expenses rose to USD 26.4 million. * Cash, cash equivalents, short-term investments, and equity investment totaled USD 215.9 million as of June 30, 2026. * Givastomig Phase 2 began in February; Fast Track secured in June, Phase 3 initiation targeted as early as year-end 2026. * VIS-101 Phase 2b expected to start in H2 2026; global Phase 3 planned for 2027, following positive Phase 2a data. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700PRIMZONEFULLFEED9813328) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)